Tenodesis means to reattach tendon or surgical fixation of a tendon. Usually, a tendon is transferred from its initial point to the new origin in order to restore muscle balance to a joint, to restore lost functions or increase active power to joint motion. Tenodesis is a procedure to attached end of the tendon to bone. Tenodesis are especially common in these areas tennis elbow, rotator cuff tendon of a shoulder, patellar tendon, gluteal tendons, Achilles tendon. Biceps Tenodesis is most common Tenodesis. During the procedure, the surgeon cuts the attachment of the biceps tendon to the labrum and then reattached it to the humerus bone. By performing a biceps tenodesis, the pressure is thereby removed from the biceps tendon in the shoulder and a portion of biceps tendon can then be surgically removed. A Biceps Tenodesis procedure is most often performed in patients over the age of 40.During a biceps tenodesis surgery procedure, a surgeon inserts a special type of screw or anchoring device into upper part of the humerus bone. The surgeon then clips off the end of a long head of the biceps and sews the remaining portion of tendon onto the screw or anchoring device so that it’s reattached to humerus instead of glenoid.
The global tenodesis devices Market is expected to witness a favorable growth during the forecast period. Increasing adoption of minimally invasive surgical procedures, technological advancements in tenodesis surgical fixation. Increasing tenodesis surgeries in the field of sports due to high overuse of body in swimming, cricket, tennis and other sports also contribute to tenodesis devices market. Moreover, increasing government investments in the field of life sciences is further contributing to the growth of the global tenodesis devices Market. Geriatric population is also a factor which contributes to the growth of global tenodesis devices market.
The global tenodesis devices Market is segmented on basis of procedure type, injury type, and end user:
Risk factors for tearing a biceps include age, overuse of the shoulder in sports require repeated arm motion, Corticosteroids, smoking. Corticosteroids drugs used for many medical conditions including joint ache have been linked to risk of the biceps tear. Tenodesis can be performed for the treatment of a number of conditions that involve the biceps tendon, including rupture of the long head of the biceps, superior labrum anterior to posterior tears, biceps tendonitis, and biceps tendinosis. Tenodesis producers can be performed with the help of arthroscopy or open surgical procedure. Screws are used for tendon repairs or reconstruction. Screw systems are eliminated transosseous tunnel drilling and graft tensioning.
Regionally, the global tenodesis devices Market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to lead the global market due to high adoption of advanced products and increasing minimally invasive surgeries in the region. However, the Tenodesis Devices Market in the Asia-Pacific region is expected to witness significant growth rate over the forecast period.
Some of the players operating in the global Tenodesis Devices Market are Arthrex, Inc., DePuy Mitek Inc, CONMED Corporation (Linvatec Corporation), Regeneration Technologies, Inc., LifeNet Health, Stryker, Tissue Regenix Group, Synthasome Inc., Parcus Medical, LLC, MedShape,Inc., Osiris Therapeutics,Inc., Rotation Medical Inc, Smith & Nephew Ltd, Musculoskeletal Transplant Foundation(MTF), Verocel.Inc, Artelon, Tissue banks, Zimmer Biomet, Integra LifeSciences Corporation, Synthasome Inc., Medtronic, AllosourceCeterix Orthopaedics, Wright Medical Group and others.
These players are highly focused on providing novel beads based DNA extraction and purification kits for rapid and reliable isolation of DNA, which is set to further stimulate the growth of the global Tenodesis Devices Market. For instance, in March 2017, Roche introduced the MagNA Pure 24 System for the extraction and purification of nucleic acids. This is an advanced instrument that is designed to extract nucleic acids from a range of human samples through a single reagent kit. Likewise, in March 2013, Aurora Biomed launched the VERSA 10 Nucleic Acid Purification Workstation. It is one of the smallest automated liquid handling workstation in the market that helps researchers to conduct large projects in limited space. Thus, innovation is set to drive the demand for automated magnetic bead-based nucleic acid instruments.
The report covers exhaustive analysis on: